Clinical commissioning policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults)

Document first published:
Page updated:
Topic:
,
Publication type:

Lomitapide is recommended to be available as a routine commissioning treatment option for homozygous familial hypercholesterolaemia within the criteria set out in this document.

Summary

Clinical evidence evaluation criteria for a proposition for a clinical commissioning policy for routine commissioning: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia.

Published 26 March 2025.

Summary

Clinical evidence review of lomitapide for treating homozygous familial hypercholesterolaemia in adults.

Published 26 March 2025.